Merck Canada Sues To Block Mylan's Generic Singulair

Law360, New York (January 3, 2012, 1:15 PM EST) -- Merck Canada Inc. on Thursday sued Mylan Pharmaceuticals Inc. in New Jersey federal court for allegedly infringing a Merck patent when it sought U.S. Food and Drug Administration approval for a generic version of the asthma treatment Singulair.

The plaintiffs — Merck Canada, Merck Frosst Canada & Co. and Merck Sharp & Dohme Pharmaceuticals — say Mylan alerted them in a Nov. 15 letter that it had lodged an abbreviated new drug application seeking a green light to make and sell its generic.

Mylan also informed...
To view the full article, register now.